NFID conference highlights influenza vaccination

These findings come as many health care professionals still report limited confidence and inconsistent practices regarding RSV immunization discussions.

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

Severe RSV disease in 2022–2023 was most likely to occur in infants under 6 months and older children with pulmonary or neurologic conditions.

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

"These findings support Advisory Committee on Immunization Practices’ recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants," wrote the MMWR study investigators.

Current prevention strategies include 2 injectables for infants and young children, namely palivizumab and nirsevimab.